BEIJING: China’s Sinopharm para bona nutun covid19 vaccine toh akhe te clinical trials nimete manishe.etu nutun recombinant Covid-19 vaccine National Vaccine & Serum Institute, R&D centre Sinopharm’s bioscience subsidiary China National Biotec Group (CNBG), para approval paishe National Medical Products Administration para Friday te.etu khobor toh CNBG para official Weibo account para Saturday te dishe.xinhua para report te janaidishe.
Etu vaccine toh structural features khan receptor-binding domain (RBD) uporte ase virus’ spike protein (S-protein) te.etu para genetic engineering chulai ase etu bi harmless copies khan bonabole nimete etu virus S-protein nimete etu bi neutralising antibodies nimete.
Etu company para statement te koikena janishe etu recombinant vaccine technology toh mature aro bhal ase large-scale production nimete.etu production toh facilities khan nalageh highly biosafety levels nimetekile koile toh etu processes toh live viruses khan nalageh.
Etu recombinant vaccine toh company’s third Covid-19 vaccine ase.juwa December te ekta inactivated vaccine bona toh Beijing Biological Products Institute Co., Ltd. Para CNBG bithor te etu toh first Chinese Covid-19 vaccine thakibo conditional marketing authorisation nimete.
February moina te aro ekta inactivated vaccine Wuhan Institute of Biological Products para ekta CNBG affiliate toh market toh conditional basis te ghussibole dibo.
Komti hoilebi 161.12 million doses of Covid-19 vaccines toh china te bonaishe Friday tak.etu toh National Health Commission para Saturday din te koikena janaishe.
Add Comment